Update on the medical management of parathyroid carcinoma
10.3760/cma.j.cn112139-20220111-00022
- VernacularTitle:甲状旁腺癌药物治疗进展
- Author:
Ming CUI
1
;
Ya HU
;
Quan LIAO
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院基本外科 疑难重症及罕见病国家重点实验室，北京 100730
- Keywords:
Parathyroid neoplasms;
Hypercalcemia;
Endocrine therapy;
Targeted therapy;
Immunotherapy
- From:
Chinese Journal of Surgery
2022;60(8):792-795
- CountryChina
- Language:Chinese
-
Abstract:
Parathyroid carcinoma is a rare endocrine malignancy with an increasing rate of incidence. Most parathyroid carcinoma patients will develop local recurrence or metastases leading to poor prognosis. Medical management is the mainstay of treatment for patients with unresectable parathyroid carcinoma. However, the therapeutic outcome of medical management remains unsatisfactory restricted by limited options and efficacy. With the deepening of research, several novel drugs have been reported to be applied in the treatment of parathyroid carcinoma. Calcimimetics and receptor activator for nuclear factor-κB ligand inhibitors aiming to control hypercalcemia have been applied in the endocrine therapy of parathyroid carcinoma. Besides, preliminary studies have shown the therapeutic effects of targeted therapy and immunotherapy on parathyroid carcinoma. These new drugs have shed light on this clinical dilemma; however, their clinical efficacy remains to be determined. In this article, the recent progress in the medical management of parathyroid carcinoma is updated.
